MDT-AP-2618
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 25.92
- os_event
- false
- age_years
- 11
- sex
- M
- new_clusters
- C5
- umap1_2d
- 5.583453632
- umap2_2d
- 4.526693724
- umap1_3d
- 2.22492971
- umap2_3d
- -0.483893423
- umap3_3d
- -1.635422942
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.360
- PANCREAS_BETA_CELLS+0.360
- SPERMATOGENESIS+0.300
- XENOBIOTIC_METABOLISM+0.270
- COAGULATION+0.230
- DNA_REPAIR+0.200
- KRAS_SIGNALING_DN+0.170
- FATTY_ACID_METABOLISM+0.160
- ADIPOGENESIS+0.140
- MYC_TARGETS_V1+0.120
Top 10 suppressed
- TGF_BETA_SIGNALING-0.380
- NOTCH_SIGNALING-0.350
- INTERFERON_ALPHA_RESPONSE-0.340
- MITOTIC_SPINDLE-0.340
- UV_RESPONSE_DN-0.320
- G2M_CHECKPOINT-0.290
- UNFOLDED_PROTEIN_RESPONSE-0.280
- MTORC1_SIGNALING-0.250
- WNT_BETA_CATENIN_SIGNALING-0.250
- APICAL_JUNCTION-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0563 | Med | Medulloblastoma | 0.810 |
| 2 | MDT-AP-2148 | Med | Medulloblastoma | 0.795 |
| 3 | MDT-AP-2120 | Med | Medulloblastoma | 0.792 |
| 4 | SRR934734 | — | — | 0.784 |
| 5 | 20090334.LumB | — | B | 0.769 |
| 6 | SRR1437538 | GTEX | — | 0.761 |
| 7 | MDT-AP-2389 | Med | Medulloblastoma | 0.758 |
| 8 | TCGA-AC-A3YJ-01A-11R-A22U-07 | — | B | 0.755 |
| 9 | MNG764 | — | — | 0.751 |
| 10 | SRR1340907 | GTEX | — | 0.751 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.360 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.360 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.270 | Inavolisib | — uncovered |
| COAGULATION | 0.230 | Binimetinib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.140 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.120 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.070 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.020 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.020 | Inavolisib | — uncovered |